SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.
Synonyms:
4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole;
FHPI;
4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1,3-dihydroimidazol-2-ylidene]cyclohexa-2,5-dien-1-one;
Properties:
Appearance & Physical State: pale yellow
Density: 1.311g/cm3
Boiling Point 565.705ºC at 760 mmHg:
Flash Point: 295.928ºC
Refractive Index: 1.653
Vapor Pressure: 0mmHg at 25°C
Ferroptosis Inhibitors Related Products:
Rosiglitazone; Bardoxolone methyl; Linagliptin; Curcumin; Troglitazone; Setanaxib; Imidazole ketone erastin